- Walgreens firing on all cylinders as chain realizes a total comp sales increase of 5.4% for its first quarter
- Bloomberg: Greg Wasson joins thought leaders to discuss the state of health care in the United States
- Walgreens offers free blood-pressure testing in support of American Heart Month
- GSK, Walgreens launch Sponsorship to Quit, a free online quit-smoking program
- Walgreens' corporate operations VP tapped to lead health care for Boots in U.K. and Ireland
WASHINGTON — Walgreens on Thursday filed a suit against the U.S. Drug Enforcement Administration over the agency's ban on Walgreens' distribution of controlled substances from a Florida facility, according to a report published by Bloomberg late Thursday evening.
Walgreens charged that the DEA relied "on 'outdated data' involving oxycodone to justify suspending distribution of the drugs from its Jupiter, Florida, facility. [Walgreens] asked the court to lift the suspension order," the report read.
Walgreens maintained there was no one allegation made by the DEA that any improper shipment originated from the company's Jupiter distribution center, or that Walgreens improperly dispensed a controlled substance from one of its pharmacies.
The case is Walgreen Co. v. Holder, 12-1397, U.S. Court of Appeals for the District of Columbia (Washington), according to the report.
For the Bloomberg story, click here.